Trial Profile
A Randomized, Head-to-Head, Single-Blind Study to Compare the Efficacy and Safety of Subcutaneous Abatacept Versus Subcutaneous Adalimumab, Both With Background Methotrexate, in Biologic-Naive Subjects With Rheumatoid Arthritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Adalimumab
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms AMPLE
- Sponsors Bristol-Myers Squibb
- 15 Nov 2023 Results assessing the prevalence of anti-PAD2, anti-PAD3 and anti-PAD4 IgG and IgA in a cohort of established RA patients, and the impact of treatment on antibody (Ab) levels, in the adalimumab vs. abatacept head-to-head active RA AMPLE study, were presented at the ACR Convergence 2023.
- 09 Nov 2021 Results (n=2087) of pooled analysis from 4 Randomized Controlled Trials (NCT00122382, NCT00929864, NCT01142726 and NCT02504268) assessing clinical outcomes among patients with SPEAR and non-SPEAR to understand the differential treatment impact of ABA on each ACR core measure, presented at the ACR Convergence 2021.
- 09 Nov 2021 Results of pooled analysis from NCT00122382, NCT00929864, NCT01142726 and NCT02504268; comparing clinical outcomes of RA patients with enriched autoantibody biomarkers and early disease stage (SPEAR) to non-SPEAR, presented at the ACR Convergence 2021